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Abstract 
Background: The choice between unit-of-use versus traditional bulk packaging in the US has long been a continuous debate for drug 
manufacturers and pharmacies in order to have the most efficient and safest practices. Understanding the benefits of using unit-of-
use packaging over bulk packaging by US drug manufacturers in terms of workflow efficiency, economical costs and medication 
safety in the pharmacy is sometimes challenging. 
Methods: A time-saving study comparing the time saved using unit-of-use packaging versus bulk packaging, was examined. Prices 
between unit-of-use versus bulk packages were compared by using the Red Book: Pharmacy’s Fundamental Reference. Other articles 
were reviewed on the topics of counterfeiting, safe labeling, and implementation of unit-of-use packaging. Lastly, a cost-saving study 
was reviewed showing how medication adherence, due to improved packaging, could be cost-effective for patients.  
Results: When examining time, costs, medication adherence, and counterfeiting arguments, unit-of-use packaging proved to be 
beneficial for patients in all these terms. 
 
 
Introduction 
Whether to use unit-of-use versus traditional bulk packaging 
is a continuous debate for drug manufacturers and 
pharmacies in order to have the most efficient and safest 
practices. The FDA published the bar code label requirement 
in February 2004 requiring manufacturers, repackers, 
relabelers, and private-label distributors of medications 
registered by the FDA to include bar codes containing at least 
the National Drug Code (NDC) of the product.
1 Since this rule, 
the use of unit-of-use packaging has increased. Many drug 
manufacturers and pharmacies in the United States decide 
not to use unit-of-use packaging mainly because of costs but 
overall unit-of-use packaging can be more safe and efficient, 
result in less counterfeiting, reduce unnecessary costs and 
ultimately prevent adverse effects. 
 
There are several types of packaging utilized in pharmacies 
across the US. A unit-of-use package is prescription 
medication that contains a quantity “designed and intended 
to be dispensed directly to a patient for a specific use without 
modification except for the addition of a prescription label by 
a dispensing pharmacist.”
2,3 Examples of unit-of-use packages 
are blister packs, compliance packs, course-of-therapy packs 
and vials containing a 30-day supply or a quantity of 
medication appropriate for specific disease state. In contrast 
and not to be confused with unit-of-use packaging, there is 
unit dose packaging. These are medications contained in a 
single unit package, readily available to be dispensed, and 
usually contain no more than a 24-hour supply of doses that 
are delivered or available to a patient-care area
4, such as in a 
hospital Pyxis. Only a small percentage of U.S. drug 
manufacturers utilize unit dose packaging, which is most 
often geared towards hospitals. Therefore, the difference 
between these two types of packaging is that unit-of-use 
packaging contains multiple doses while unit dose packaging 
contains one dose.
5 Bulk packaging contains one type of 
medication per package intended for multiple single doses.
6  
 
Realistic Example: Unit-of-Use Efficiency 
Implementing more unit-of-use packaging could reduce 
pharmacy workload by eliminating some of the tedious 
dispensing tasks. Examples of these are, returning stock 
bottles to storage shelves, retrieving dispensing vials, and 
measuring dosage units.
2 A unit-of-use time savings study 
carried out by Lipowski et al. in a community pharmacy 
analyzed the time saved between dispensing unit-of-use 
versus bulk packaging. The authors conducted a simulation 
study where they compared two teams in regards to their 
accuracy and time spent to prepare medications according to 
the assigned packaging method. The first team prepared a set 
of 50 prescriptions using the bulk packaging method and then 
filled a set of 50 prescriptions using the unit-of-use packaging 
method. The second team prepared the same number of 
prescriptions but used the unit-of-use packaging method first, 
then used the bulk packaging method. Each team consisted of 
a pharmacist and a technician who prepared the prescriptions 
using both methods in order to minimize confounding factors 
and bias. When using the unit-of-use packaging method, the 
first and second team accomplished prescription preparation 
in 19.5 minutes and 20.5 minutes, respectively (see Table 1). 
In contrast, bulk packaging took longer to accomplish, taking 
the first and second team 45 minutes and 41.5 minutes, 
respectively.
 Between these two teams, the average time Student Projects  PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                         2012, Vol. 3, No. 1, Article 68                        INNOVATIONS in pharmacy    2 
 
saved by using unit-of-use packages, for 50 prescriptions, was 
23.25 minutes or approximately 28 seconds per prescription.
2 
 
This study also looked at the amount of time pharmacists 
were involved in actual prescription assembly versus 
cognitive activities that could be accomplished during the 
simulation such as reviewing prescription orders, finding drug 
interactions, counseling patients, and calling health care 
providers. Pharmacists were involved in prescription 
assembly for 26% of the bulk packaged orders versus only 4% 
of the unit-of-use packaged orders (see Table 1).  
 
The last component of the study analyzed medication errors 
and found four counting errors when processing bulk-
packaged prescriptions, two per team, versus zero for the 
unit-of-use packaging. This study showed that implementing 
unit-of-use packaging in a retail setting significantly reduces 
the amount of time a pharmacist is involved in medication 
dispensing, allows more time for other activities, such as 
counseling, and decreases counting errors.
2  
 
Limitation: Costs 
Many drug manufacturers view the cost of packaging as a 
limiting factor of using unit-of-use packaging over traditional 
bulk packaging.  The U.S. Barrier Packaging study conducted 
in 2002, showed 85% of all medications were in bulk 
packaging while the other 15% were in either unit dose or 
unit-of-use packages used mostly for physician samples or 
hospital medications.
7 National surveys conducted by the 
NCPA in 2000 and APhA in 1985 also showed that more bulk 
packages were purchased due to unit-of-use packages being 
more expensive for consumers.
5,8 There has been no 
significant event that has changed the current trend of unit-
of-use packaging being more expensive. The time-saving 
study by Lipowski et al. also estimated the actual acquisition 
cost (AAC) of bulk packages versus similar unit-of-use 
packages. Of the 50 types of prescriptions used in the 
Lipowski et al. study, they reported the unit-of-use packages 
cost $6.31 more.
2 The unit-of-use method tends to consist of 
more expensive packaging due to the need for an increased 
amount of packaging and labeling materials (see Table 2).  
 
Average drug prices can be found in the Red Book: 
Pharmacy’s Fundamental Reference, from which Table 2 is 
derived.
9 Table 2 shows that the alprazolam was cheaper in 
2006 when bought in bulk packaging, at the expense of 
$59.00 for 100 tablets versus the unit-of-use packaging price 
of $61.67 for 100 tablets. Hydrochlorothiazide and 
methylprednisolone follow the same trend as alprazolam, 
with the unit-of-use price being slightly higher than the bulk 
price. In contrast, azithromycin when purchased with unit-of-
use and bulk packaging had the same price of $46.66 per 18 
tablets despite the types of packaging used.
9 Omeprazole 
shows an exception where not all medications are cheaper in 
bulk pricing but are less with the unit-of-use pricing. The last 
example presented in Table 2 is simvastatin that shows no 
price difference between the unit-of-use pricing and bulk 
pricing despite the number of units purchased.
9 Whether 
purchasing 30, 90, or 1,000 simvastatin tablets, the price of  
$5.25 per tablet remains the same. Most medication prices 
may vary depending on the manufacturer chosen, quantity, 
and type of packaging. Although this is a small medication 
pricing example of common medications purchased, it 
exhibits the general trend that unit-of-use medications are 
generally more expensive than bulk packaged medications.  
 
In the case of the Lipowski et al. study, eliminating the cost of 
separate prescription vials, decreased counting errors, and 
the time saved can offset the increased cost of the unit-of-
use packaging. Another study by Heaton et al. supports the 
Lipowski et al. study that by using unit-of-use packaging, it 
can decrease overall inventory costs. This is due to requiring 
fewer units in stock at any given time therefore, increases 
inventory turnover and cash flow.
2,10 A downfall of unit-of-
use packaging is the increased need for storage area needed, 
which is limited in many pharmacies, especially in the urban 
setting. However, no longer needing space for prescription 
vials would help counteract the storage space problem for 
medications. 
 
Improved Product Labeling 
When labeling is provided by a drug manufacturer, unit-of-
use packaging offers several labeling advantages compared to 
bulk packaging. First, a unit-of-use dosage form can be 
dispensed in its original container. This allows the counting 
and repackaging of dosage units in the pharmacy to be 
eliminated and therefore reducing human error. Patient 
compliance may be improved by each unit dose being labeled 
and more recognized when a dose is missed.
11 For example, 
patients can clearly see if they have missed a dose when one 
of their blisters is unopened in their 30-day blister packet 
supply. Patients maybe then more compelled to finish all 30 
days of the prescription. Still, patients should be instructed 
on how to handle missed doses and how to avoid overdosing 
on medications if a dose is missed.  
 
Counting errors in the prescription dispensing process have 
implications for customer relations, inventory management, 
and therapeutic outcomes.
2 Not receiving the correct 
quantity of medication, may cause patients to distrust the 
pharmacy and result in less than ideal patient care. 
Dispensing excess medication to a patient increases costs to a 
pharmacy and could eventually lead to adverse events for a 
patient. Unit-of-use packaging promotes patient safety by Student Projects  PHARMACY PRACTICE 
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improving sanitary, patient compliance, and product 
identification through the inclusion of bar codes, 
manufacturer, expiration date, and lot number on the label in 
the event of product recall. Unit-of-use packaging also makes 
drug counterfeiting more difficult because the packaging, as 
well as the drug, must be replicated exactly the same as the 
original manufacturer.
12  
 
Counterfeiting is a significant problem in the field of 
pharmaceuticals worldwide, causing an increase in costs and, 
worst of all, a threat to patient safety. The World Health 
Organization (WHO) is working with the International 
Criminal Police Organization (Interpol) to help decrease the 
billions of dollars lost due to this illegal trade. In 2009, 
Interpol seized approximately 20 million pills, bottles and 
sachets of counterfeit and illegal medicines in a five month 
operation in China and nearby Asian countries. Asia has the 
largest amount of counterfeit medications but these illegal 
acts can be found worldwide.
13 Attaining accurate 
estimations of the money lost in counterfeit medications is 
difficult since there is a large number of sources and 
information that contribute to these scandals. This problem 
has vastly expanded due to Internet sales. The WHO reports 
that over 50% of the counterfeit cases are due to illegal 
medication Internet sites.
13 Not only are large amounts of 
money lost but also lives. In 2008, for example, 150 people in 
Singapore were hospitalized for having severe hypoglycemia. 
Several deaths occurred and others suffered severe brain 
damage due to taking counterfeit medications that were 
supposed to treat erectile dysfunction but instead contained 
large doses of glyburide, a medication used for diabetes.
13 
The cost of implementing safety programs is minimal 
compared to the loss of a life or lives because of counterfeit 
medications. Increasing unit-of-use packaging can help 
decrease the act of medication counterfeiting because of the 
arduous method needed to duplicate both individual 
medication packages and medications. Although unit-of-use 
packaging would initially increase costs for drug 
manufacturers, the long-term effect would greatly triumph 
this by decreasing the number of adverse effects and possible 
deaths. 
 
Cost-Saving Example from Stroke Prevention 
Unit-of-use packaging has been shown to increase medication 
adherence amongst patients, because of the ease of taking 
medications and ease of recognition when a dose has been 
missed. Taking a look at an idealistic example of the cost 
effectiveness due to medication adherence of a hypertensive 
medication shows its impact of decreasing long-term costs by 
preventing patient adverse events.  
 
 One study by Cherry et al. looked at the clinical and 
economic burden of non-adherence with antihypertensive 
and lipid-lowering therapy in hypertensive patients. They 
determined lifetime costs, morbidity, and mortality 
associated with three types of medication adherences: no 
treatment, ideal adherence, and real-world adherence. The 
study simulated patients’ characteristics matching those of 
the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid 
Lowering Arm and event probabilities were calculated with 
the Framingham Heart Study risk equations.
14 For the purpose 
of this article, only the arm of the primary stroke patients will 
be reviewed in regards to the effect of medication adherence 
on costs. 
 
This study estimated the cost difference, consisting of 
hospitalizations, physician costs, and annual institutional 
care, between varying adherence scenarios. Of the three 
types of adherence scenarios, the ideal adherence was used 
in this study as the gold standard. Cherry et al. found patients 
with no treatment accrued treatment costs of $12,800, with 
increased patient lives by 14.73 months and had 0.74 more 
cardiac events (see Table 3). In comparison, real-world 
adherence accrued costs of $23,300, increased patient lives 
by 15.07 months and resulted in 0.61 more cardiac events 
while ideal adherence accrued costs of $32,500 increased 
patient lives by 15.49 months, and resulted in 0.44 more 
cardiac events. When compared with no treatment, real-
world adherence patients had a longer life expectancy while 
ideal adherence patients had an even longer life expectancy 
in regards to patients adhering to taking their anti-
hypertensive therapy. While it may seem that no treatment 
would have less direct medical costs per patient due to not 
taking any medications, this study found that patients with 
ideal adherence saved $22,000 per life-year gained which 
cancels out the low costs of no treatment and highlights the 
burden of more cardiac events. Patients with real-world 
adherence saved $31,000 per life-year gained. Cherry et al. 
also applied their findings prospectively to a larger population 
model. In a population of 10,000 patients, 6100 lifetime 
stroke events would be expected as real-world adherence. 
With ideal adherence, 1700 (28%) of the 6100 events would 
be avoided.
14 
 
Although the Cherry et al. article attempted to avoid any 
biases, there were some limitations related to assumptions 
on adherence rates and effectiveness of the anti-
hypertensive therapy. They noted that these costs may not 
be as relevant to date because of amlodipine losing patent 
protection in the United States in 2007 and can now be 
acquired at lower costs. However, amlodipine was one of the 
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the impact of this price would have not changed the average 
daily WAC significantly.  
 
Overall, in patients with hypertension and cardiovascular risk 
factors lost more than half of the potential benefits from anti-
hypertensives due to poor adherence. Anti-hypertensives are 
cost-effective at real-world adherences and even more so at 
ideal adherences. Cherry et al. supported an intervention, 
depending on costs of implementation, to improve 
adherence as means to increase the cost effectiveness of 
health care.
14 Patients have multiple reasons to be non-
compliant such as financial constraints, denial, mistrust, and 
intolerable side effects. In specific, utilizing more unit-of-use 
medication packaging, can be one intervention to help 
compliance of patients. 
 
Implementing Unit-of-Use Packaging 
Most developed countries have implemented unit-of-use 
packaging, including Canada, Australia, New Zealand, and 
other countries in Europe and South America.
5 Implementing 
unit-of-use packaging may be difficult in the United States, 
requiring substantial changes in manufacturing, dispensing, 
and storage of medications. Not only would the physical 
processes of producing medications need to change, but also 
prescribing practices and therefore governing policies of 
prescribing. In order to increase unit-of-use packaging, there 
would have to be multiple negotiations made between 
manufacturers, prescribers, pharmacists, government 
agencies, and consumers. 
 
The main area of conflict between unit-of-use and traditional 
bulk packaging lies in the retail market. Many health care 
providers see unit-of-use packaging as an opportunity for 
pharmacists and technicians to save time and therefore 
money, by reducing the processes of counting pills, filling, 
and labeling.
2,10 In time, health care providers will need to 
perform precise return-of-investment analyses on how their 
products are packaged and marketed to consumers. If the 
increased expense of unit-of-use packaging can be justified by 
the high return-on-investment, then soon the slow trend 
toward utilizing unit-of-use packaging will turn into a race 
amongst health care providers.
13  
 
Statistics show the number of outpatient prescriptions 
processed in the US is constantly increasing, since there is a 
larger aging generation needing more medications.
2 
However, the number of pharmacies remains constant in the 
retail setting. This imbalance between the number of 
pharmacies and growing number of prescriptions warrants 
serious consideration of the changing retail pharmacy 
practice and efficiency improvements in prescription 
dispensing.
2 Increasing unit-of-use packaging in the retail 
market can decrease the amount of time pharmacists are 
needed for dispensing and allow more time for reviewing 
patients’ medication profiles, especially with the increasing 
number of prescriptions and related counseling of patients, 
including medication therapy management. 
 
Although buying bulk packaging is cheaper and more suitable 
for pharmacy automation systems, looking at the expenses of 
unit-of-use versus traditional bulk packaging can ultimately 
lead to a more efficient process and safer practice in 
medication dispensing. Choosing the correct medication 
packaging method is important to drug manufacturers and 
will continue to grow in the future. The continual innovation 
and development of material packaging was not mentioned 
in this article but is crucial to drug manufacturers when 
meeting demands of storing and delivering medications to 
patients. There are now many advanced ways of storing 
medications in unit-of-use packaging that cannot be 
accomplished by bulk packaging such as orally disintegrating 
dosage forms.
7 Utilizing more unit-of-use packaging can be 
beneficial from a multitude of perspectives in the 
pharmaceutical industry. Whether analyzing cost, 
compliance, or counterfeiting, the safety of patients should 
be the ultimate motivation to use unit-of-use packaging. 
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Table 1. Lipowski Study: Unit-of-Use Method versus Bulk Method
2 
 
  Unit-of-Use Method 
(50 Prescriptions) 
Bulk Method 
(50 Prescriptions) 
Team 1  19.5 minutes  45 minutes 
Team 2  20.5 minutes  41.5 minutes 
     
Usage of Pharmacists in Rx 
Assembly 
4%  26% 
Number of Errors  0   4  
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Table 2. Comparing Red Book Unit-of-Use vs. Bulk Prices
8 
 
Drug  Manufacturer  Dosage  # of 
pills/ 
bottle 
Unit-of-
Use 
Price/  
bottle  
($) 
Unit-of-
Use 
Price/  
pill ($) 
Bulk 
Price/   
bottle 
($) 
Bulk 
Price/  
pill ($) 
               
Alprazolam  Greenstone  0.25 mg  100  61.67  0.62     
  Cardinal Pharm  0.25 mg  100      59.00  0.59 
               
Azithromycin  Pliva, Inc.  250 mg  18  139.99  7.78  -  - 
      30      233.33  7.78 
               
Hydrochlorothiazide  GSMS  25 mg  90  11.55  0.13  -  - 
  Heartland  25 mg  30  2.81  0.09  -  - 
      90  9.42  0.09     
  PCA, LLC  25 mg  30  -  -  2.00  0.07 
      90  -  -  4.00  0.04 
               
Methylprednisolone  Breckenridge 
Pharm 
4 mg  21  11.00  0.52  -  - 
  Qualitest  4 mg  21  10.65  0.51  -  - 
      100      48.40  0.48 
               
Omeprazole  UDL  20 mg  100  390.00  3.90  -  - 
  Teva  20 mg  100  -  -  415.15  4.15 
  Apotex  20 mg  100  -  -  415.14  4.15 
               
Simvastatin  Merck  40 mg  30  157.45  5.25  -  - 
      90  472.37  5.25  -  - 
      1000  -  -  5249  5.25 
 
 
 
 
Table 3. Cost-effectiveness over Lifetime
14 
 
Adherence 
scenario 
Costs  Patient-years  Events  Savings 
 No treatment  12,800  14.73  0.74  __ 
 Real-world  23,300  15.07  0.61  31,000 
 Ideal  32,500  15.49  0.44  22,000 
 
 